Shinohara H, Yonekawa H, Machimura T, Furukawa T, Nishihori H, Kurihara N, Urakami H, Nemoto Y
Dept. of Surgery, National Ohkura Hospital.
Gan To Kagaku Ryoho. 1998 Feb;25(3):397-402.
Efficacy of combination of ondansetron injection and tablet on CAF (cyclophosphamide, adriamycin, 5-fluorouracil) induced emesis were investigated in 10 breast cancer patients (33 courses). Complete suppression rate of nausea or vomiting were approximately 75%, approximately 90% respectively for every treatment day. According to judgement criteria, antiemetic rate of approximately 100% was achieved during the study period. As to food intake of each treatment day, in approximately 70% of treatment courses was assessed as '(patient was) able to eat most of the meal'. Trend in emetic episodes and food intake in each patient receiving several courses of CAF therapy were evaluated. As a result, those patients experiencing nausea or vomiting or had effect on their food intake, were found to be in the similar condition in the following course (s) of CAF. No adverse drug reaction nor clinical laboratory test abnormalities due to ondansetron was observed. In this investigation, combination of ondansetron injection and tablet was shown to sufficiently suppress CAF-induced nausea and vomiting, and their efficacy was confirmed. Still, the study suggested that number of emetic episodes or degree of anorexia differs according to each individual. Therefore we regard additional administration of ondansetron or concomitant use of steroids should be considered when necessary.
在10例乳腺癌患者(共33个疗程)中研究了昂丹司琼注射剂与片剂联合使用对环磷酰胺、阿霉素、5-氟尿嘧啶(CAF)所致呕吐的疗效。在每个治疗日,恶心或呕吐的完全抑制率分别约为75%和约90%。根据判断标准,在研究期间达到了约100%的止吐率。关于每个治疗日的食物摄入量,约70%的治疗疗程被评估为“(患者)能够吃大部分食物”。评估了接受多个疗程CAF治疗的每位患者的呕吐发作趋势和食物摄入量。结果发现,那些经历恶心或呕吐或对食物摄入量有影响的患者,在随后的CAF疗程中情况相似。未观察到因昂丹司琼引起的药物不良反应或临床实验室检查异常。在本研究中,昂丹司琼注射剂与片剂联合使用显示出能充分抑制CAF引起的恶心和呕吐,其疗效得到了证实。尽管如此,研究表明呕吐发作次数或厌食程度因个体而异。因此,我们认为必要时应考虑额外给予昂丹司琼或同时使用类固醇。